{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:21:54Z","timestamp":1783344114505,"version":"3.54.6"},"reference-count":30,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objective: Romosozumab carries a warning for potential severe cardiovascular events, while denosumab is widely used for osteoporosis but requires safety considerations in advanced chronic kidney disease (CKD). Given the limited direct real-world evidence comparing these treatments, in this study, we aimed to compare the cardiovascular and survival outcomes associated with romosozumab versus denosumab in adults with CKD. Materials and Methods: In this retrospective propensity score-matched cohort study, we utilized de-identified electronic health records from the TriNetX Global Collaborative Network, where eligible participants were adults aged 40 to 90 years with CKD who initiated either romosozumab or denosumab. Patients with bone\/bone marrow malignancies or recent acute cardiovascular events were excluded. Following 1:1 propensity score matching based on demographics, diagnoses, medications, and laboratory characteristics, patients were followed for up to 1095 days. The primary outcome was a composite cardiovascular measure (all-cause mortality, acute myocardial infarction, or cerebrovascular event), while secondary outcomes included the individual components of the composite outcome and acute heart failure. Outcomes were evaluated using fixed-window cumulative risks, risk ratios (RRs), odds ratios, and hazard-ratio estimates. Results: After 1:1 propensity score matching, 1201 patients remained in each cohort; the mean age was 74.1 years in the romosozumab cohort and 74.2 years in the denosumab cohort, and 94.9% and 93.8%, respectively, were women. Romosozumab was associated with lower 1095-day cumulative risk of the composite cardiovascular outcome than denosumab (12.6% vs. 18.8%; RR, 0.668 [95% CI, 0.553\u20130.808]), as well as lower cumulative risk of cerebrovascular event (5.0% vs. 7.0%; RR, 0.714 [95% CI, 0.518\u20130.985]), all-cause mortality (6.6% vs. 9.5%; RR, 0.693 [95% CI, 0.526\u20130.913]), acute myocardial infarction (3.8% vs. 6.2%; RR, 0.613 [95% CI, 0.429\u20130.878]), and heart failure (2.7% vs. 6.1%; RR, 0.438 [95% CI, 0.292\u20130.659]). Conclusions: In this propensity score-matched EHR cohort of adults with CKD, cardiovascular and survival estimates associated with romosozumab versus denosumab varied by follow-up window and analytic approach. Although 1095-day fixed-window cumulative risks were lower in the romosozumab cohort, corresponding time-to-event estimates were neutral or directionally inconsistent. These findings should not be interpreted as evidence of cardioprotection or causal superiority but rather as showing no clear and consistent excess cardiovascular risk signal for romosozumab compared with denosumab.<\/jats:p>","DOI":"10.3390\/medicina62071302","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:43:11Z","timestamp":1783334591000},"page":"1302","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Outcomes Associated with Romosozumab Versus Denosumab in Chronic Kidney Disease"],"prefix":"10.3390","volume":"62","author":[{"given":"Jheng-Yan","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Neurological Institute, Taichung Veterans General Hospital, No. 1650, Taiwan Boulevard Sect. 4, Taichung 40705, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3529-1867","authenticated-orcid":false,"given":"Tse-Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Neurological Institute, Taichung Veterans General Hospital, No. 1650, Taiwan Boulevard Sect. 4, Taichung 40705, Taiwan"},{"name":"Doctoral Program in Translational Medicine, National Chung Hsing University, Taichung 40227, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7378-4211","authenticated-orcid":false,"given":"Kuan-Kai","family":"Tung","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Taichung Veterans General Hospital, Taichung 40705, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Lien","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Nursing, Taichung Veterans General Hospital, Taichung 40705, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4201-465X","authenticated-orcid":false,"given":"Cheng-Ying","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Neurological Institute, Taichung Veterans General Hospital, No. 1650, Taiwan Boulevard Sect. 4, Taichung 40705, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7998-6607","authenticated-orcid":false,"given":"Chi-Ruei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Neurological Institute, Taichung Veterans General Hospital, No. 1650, Taiwan Boulevard Sect. 4, Taichung 40705, Taiwan"},{"name":"Department of Neurosurgery, Taichung Veterans General Hospital Puli Branch, Nantou County 545402, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, Chung Shan Medical University, Taichung 40201, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsu-Tung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Neurological Institute, Taichung Veterans General Hospital, No. 1650, Taiwan Boulevard Sect. 4, Taichung 40705, Taiwan"},{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 40227, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Shen, Y., Huang, X., Wu, J., Lin, X., Zhou, X., Zhu, Z., Pan, X., Xu, J., Qiao, J., and Zhang, T. (2022). The Global Burden of Osteoporosis, Low Bone Mass, and Its Related Fracture in 204 Countries and Territories, 1990\u20132019. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.882241"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/jama.2025.6003","article-title":"Osteoporosis: A review","volume":"334","author":"Morin","year":"2025","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.2009.50","article-title":"Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women","volume":"301","author":"Bliuc","year":"2009","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S2213-8587(17)30310-8","article-title":"Bone and mineral disorders in chronic kidney disease: Implications for cardiovascular health and ageing in the general population","volume":"6","author":"Covic","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jbmr\/zjae021","article-title":"Risk factors for hip and vertebral fractures in chronic kidney disease: The CRIC study","volume":"39","author":"Hsu","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1007\/s00198-022-06462-3","article-title":"Management of osteoporosis in patients with chronic kidney disease","volume":"33","author":"Abdalbary","year":"2022","journal-title":"Osteoporos. Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/MNH.0000000000001084","article-title":"Effects of aging on chronic kidney disease mineral and bone disorder","volume":"34","author":"Dalboni","year":"2025","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S2213-8587(14)70059-2","article-title":"Bone: A new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders","volume":"2","author":"Vervloet","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Williams, M.J., White, S.C., Joseph, Z., and Hruska, K.A. (2023). Updates in the chronic kidney disease-mineral bone disorder show the role of osteocytic proteins, a potential mechanism of the bone-vascular paradox, a therapeutic target, and a biomarker. Front. Physiol., 14.","DOI":"10.3389\/fphys.2023.1120308"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-021-06095-y","article-title":"A systematic review and meta-analysis of efficacy and safety of romosozumab in postmenopausal osteoporosis","volume":"33","author":"Singh","year":"2022","journal-title":"Osteoporos. Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1210\/clinem\/dgab193","article-title":"Cardiovascular Safety and Sclerostin Inhibition","volume":"106","author":"Langdahl","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"ACOG Committee on Clinical Practice Guidelines\u2013Gynecology (2022). Management of Postmenopausal Osteoporosis: ACOG Clinical Practice Guideline No. 2. Obstet. Gynecol., 139, 698\u2013717.","DOI":"10.1097\/AOG.0000000000004730"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/S0140-6736(25)01385-6","article-title":"Osteoporosis","volume":"406","author":"Ye","year":"2025","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7326\/M22-1034","article-title":"Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline from the American College of Physicians","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40264-024-01475-9","article-title":"Cardiovascular safety of romosozumab compared to commonly used anti-osteoporosis medications in postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials","volume":"48","author":"Cheng","year":"2025","journal-title":"Drug Saf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e861","DOI":"10.1210\/clinem\/dgae173","article-title":"Cardiovascular safety of romosozumab vs PTH analogues for osteoporosis treatment: A propensity-score-matched cohort study","volume":"110","author":"Stokar","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"eaay6570","DOI":"10.1126\/scitranslmed.aay6570","article-title":"Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics","volume":"12","author":"Bovijn","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/jamainternmed.2025.1488","article-title":"Denosumab and Fracture Prevention in Primary Care Practice","volume":"185","author":"Bauer","year":"2025","journal-title":"JAMA Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"115121","DOI":"10.1016\/j.bone.2019.115121","article-title":"Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta-analysis","volume":"130","author":"Lv","year":"2020","journal-title":"Bone"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jbmr.4157","article-title":"Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta-Analysis of Randomized Trials","volume":"36","author":"Seeto","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1210\/clinem\/dgaa851","article-title":"Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study with Mild to Moderate Chronic Kidney Disease","volume":"106","author":"Broadwell","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/jbmr.3019","article-title":"Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients with Osteoporosis: A Cohort Study","volume":"32","author":"Choi","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ludwig, R.J., Anson, M., Zirpel, H., Thaci, D., Olbrich, H., Bieber, K., Kridin, K., Dempfle, A., Curman, P., and Zhao, S.S. (2025). A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1516126"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.17.00067","article-title":"Using a federated network of real-world data to optimize clinical trials operations","volume":"2","author":"Topaloglu","year":"2018","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., Gotzsche, P.C., and Vandenbroucke, J.P. (2007). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. PLoS Med., 4.","DOI":"10.1371\/journal.pmed.0040296"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11914-020-00652-w","article-title":"Romosozumab: A Review of Efficacy, Safety, and Cardiovascular Risk","volume":"19","author":"Fixen","year":"2021","journal-title":"Curr. Osteoporos. Rep."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/7\/1302\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:08:44Z","timestamp":1783343324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/7\/1302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["medicina62071302"],"URL":"https:\/\/doi.org\/10.3390\/medicina62071302","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}